Citations in PubMed

Primary Citation PubMed: 9338790 Citations in PubMed

PDB ID Mentions in PubMed Central Article count: 15

Citations in PubMed

This linkout lists citations, indexed by PubMed, to the Primary Citation for this PDB ID.

PDB ID Mentions in PubMed Central

Data mentions are occurrences of PDB IDs in the full text articles from the PubMedCentral Open Access Subset of currently about 1 million articles. For each article, the sentences containing the PDB ID are listed. Article titles can be filtered by keywords and sorted by year.

  • 3 per page
  • 5 per page
  • 10 per page
  • view all
  • Publication Year
  • Ascending
  • Descending

Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease.

(2006) BMC Neurosci 7

PubMed: 16533397 | PubMedCentral: PMC1421415 | DOI: 10.1186/1471-2202-7-24

Figure 3 Superimposition of 3D complex models of ERα with 17β-estradiol (dark red; PDB ID: 1ERE), equilin (blue), Δ 8,9 -dehydroestrone (green) and estrone (purple) .

Publication Year: 2006


Protein evolution by molecular tinkering: diversification of the nuclear receptor superfamily from a ligand-dependent ancestor.

(2010) PLoS Biol 8

PubMed: 20957188 | PubMedCentral: PMC2950128 | DOI: 10.1371/journal.pbio.1000497

In each case, we used as templates crystal structures of several NR LBDs with a variety of cavity volumes, including human ERα with estradiol (PDB 1ERE:A, cavity volume 447 Å 3 ), huma... ERR3 apo form (1KV6:A, cavity volume 262 Å 3 ), human ERR1 apo form (3D24:A, cavity volume 42 Å 3 ), and AqNR1 as modeled on template HNF4A with DAO (1MV7:A, cavity volume 680 Å 3 ).

Publication Year: 2010


Survey of public domain software for docking simulations and virtual screening.

(2011) Hum Genomics 5

PubMed: 21807604 | PubMedCentral: PMC3525969 | DOI: null

The docking simulations for programs surveyed here were performed using E2-, raloxifen- and tamoxifen-bound crystal structures of the ligand binding domain of ER alpha (PDB codes 1ERE , 1ERR and 3ERT ... , using re-docking of native ligands to test if user-defined parameters and the simulation systems (including the grid box) had been properly set up for each of the programs.

Publication Year: 2011


Estrogenic potency of benzophenone UV filters in breast cancer cells: proliferative and transcriptional activity substantiated by docking analysis.

(2013) PLoS One 8

PubMed: 23593250 | PubMedCentral: PMC3617139 | DOI: 10.1371/journal.pone.0060567

Computer-simulated ligand binding (docking) Protein input file preparation A clean Estradiol receptor α input file (1ERE pdb, referred to in this paper as ER-E2) was generated using the protei... preparation wizard from Maestro software (Maestro 8.5, academic campaign, Schrodinger website.

Publication Year: 2013


Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor ? and ? subtypes: a molecular modeling study.

(2013) PLoS One 8

PubMed: 24098659 | PubMedCentral: PMC3786999 | DOI: 10.1371/journal.pone.0074615

ER isoform Ligands PDB code References Comments ERα-LBD E 2 1ERE [14] The first steroid receptor structure with an agonist bound inside the LBD.

To determine whether the computational docking approach can produce the same binding mode for DES as observed in the crystallographic study, we performed a cross-docking validation by using the crystal structure of the human ERα LBD in complex with E 2 (PDB code: 1ERE) as a template receptor for the docking of DES.

Therefore, in this study, the x -ray crystal structure of human ERα in complex with E 2 (PDB code: 1ERE) [14] and the x -ray crystal structure of human ERβ in complex with a synthetic ERβ agonist ERB-041 (PDB code: 1X7B) [18] were used as templates for docking various estrogen derivatives.

We compared the ERα structures in complex with three ERα agonists, namely, E 2 (PDB codes 1ERE and 1A52), DES (PDB code 3ERD), and genistein (GEN) (PDB code 1X7R) by superimposing these structures on each other.

The docking results were compared with the known crystal structure of the ERα-E 2 complex (PDB code: 1ERE).

Publication Year: 2013


Integration of ligand-based drug screening with structure-based drug screening by combining maximum volume overlapping score with ligand docking.

(2012) Pharmaceuticals (Basel) 5

PubMed: 24281339 | PubMedCentral: PMC3816669 | DOI: 10.3390/ph5121332

A complex of ER- α with estrogen (PDB ID: 1ere) was selected as the template and the ligands of the other complex structures were docked into ER- α pocket ( Table 4 ).

Publication Year: 2012


Vestigialization of an allosteric switch: genetic and structural mechanisms for the evolution of constitutive activity in a steroid hormone receptor.

(2014) PLoS Genet 10

PubMed: 24415950 | PubMedCentral: PMC3886901 | DOI: 10.1371/journal.pgen.1004058

Homology modeling of the AncLophoSR structure A homology model for the AncLophoSR:estradiol complex was generated using the functionally similar human ERα:estradiol complex (1ERE) as a guide.

Publication Year: 2014


Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets.

(2009) Acta Pharmacol Sin 30

PubMed: 19935678 | PubMedCentral: PMC4007494 | DOI: 10.1038/aps.2009.159

Target PDB entries a Number of Actives b ACE 1UZF, 1O86, 1UZE * 14 AChE 1ACJ, 1ACL, 1AMN, 1AX9, 1DX6, 1E3Q, 1E66, 1EVE, 1GPK, 1GPN, 1GQR, 1GQS, 1H22, 1H23, 1HBJ, 1JJB, 1OCE, 1ODC, 1U65, 1UT6, ... VOT, 1W4L, 1W6R, 1W76, 1ZGC, 2ACE, 2ACK * , 2BAG, 2C4H, 2C5F, 2C5G, 2C58, 2CEK, 2CKM, 2CMF, 2J3Q, 2VB4 22 AR 1E3G * , 1GS4, 1T5Z, 1T63, 1T65, 1XJ7, 1XOW, 1XQ3, 1Z95, 2AM9, 2AMA, 2AMB, 2AO6, 2AX6, 2AX7, 2AX8, 2AX9, 2AXA, 2HVC, 2OZ7, 2PIO, 2PIP, 2PIQ, 2PIR, 2PIT, 2PIU, 2PIV, 2PIW, 2PIX, 2PKL, 2PNU, 2Q7I, 2Q7J, 2Q7K, 2Q7L, 2Z4J 16 DacA 1CEF, 1CEG * , 1HVB, 1IKG, 1IKI, 1MPL, 1PW1, 1PW8, 1PWC, 1PWD, 1PWG, 1SCW, 1SDE, 1YQS 3 DHFR 1BOZ * , 1KMS, 1KMV, 1S3U, 1S3V, 1S3W, 2DHF, 1DLS, 1U72, 1MVS, 1MVT, 1DLR, 1U71, 1HFP, 1HFQ, 1HFR, 1OHJ, 1OHK, 1DHF, 1DRF, 1PD8, 1PD9 8 ERα 1A52, 1AKF, 1ERE, 1ERR, 1G50, 1GWQ, 1GWR, 1L2I, 1PCG * , 1QKT, 1R5K, 1UOM, 1X7E, 1X7R, 1XP1, 1XP6, 1XP9, 1XPC, 1YIM, 1ZKY, 2AYR, 2B1V, 2B1Z, 2BJ4, 2FAI, 2G44, 2G5O, 2I0J, 2IOG, 2JF9, 2JFA, 2OUZ, 2P15, 2POG, 2Q6J, 2Q70, 2QE4, 3ERD, 3ERT 32 HIV-pr 1AID, 1HVH, 1HVR, 1HWR, 1IZH, 1IZI, 1JLD, 1KZK, 1NPV, 1NPW, 1T3R, 1T7K, 1TCX, 1XL2, 1XL5, 1YT9, 2A4F * , 2AID, 2F3K, 2FDD, 2FDE, 2FGU, 2FGV, 2HC0, 2NXD, 2NXM, 2P3A, 2P3B, 2P3C, 2P3D, 3AID, 4PHV 9 TK 1E2I, 1E2J, 1E2K * , 1E2L, 1E2M, 1E2N, 1E2P, 1KI2, 1KI3, 1KI4, 1KI6, 1KI7, 1KI8, 1KIM, 1OF1, 1P7C, 1QHI, 1VTK, 2KI5, 2VTK, 3VTK 8 a All the X-ray crystal structures of the complexes of each target in complex with ligands were used in the construction of pharmacophore models.

Publication Year: 2009


Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network.

(2014) Elife 3

PubMed: 24771768 | PubMedCentral: PMC4017646 | DOI: 10.7554/eLife.02057

Brzozowski AM , Pike AC , Dauter Z , Hubbard RE , Bonn T , Engstrom O , Ohman L , Greene GL , Gustafsson JA , Carlquist M , 1997 , Human Estrogen Receptor Ligand-Binding Domain in Comples With 17beta-... stradiol , http://www.rcsb.org/pdb/explore/explore.do?structureId=1ere , Publicly available at RCSB Protein Data Bank.

PDB ID: 1ERE.

Publication Year: 2014


Rational modification of estrogen receptor by combination of computational and experimental analysis.

(2014) PLoS One 9

PubMed: 25075862 | PubMedCentral: PMC4116177 | DOI: 10.1371/journal.pone.0102658

The calculations showed the presence of 54% α-helical secondary structure for all the wild-type and the mutants which reflects well the secondary structure elements derived from the available ... hree dimensional structure of wt-ER α LBD (PDB: 1ERE).

Publication Year: 2014


Exogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptors.

(2014) Curr Med Chem 21

PubMed: 24304271 | PubMedCentral: PMC4153070 | DOI: null

Superposing the three-dimensional structure of the ERα:E2 complex (PDB code 1ERE) with the ERα:raloxifene complex (PDB code 1ERR), a large movement of helix H12 immediately comes to li... ht.

Publication Year: 2014


Versatility or promiscuity: the estrogen receptors, control of ligand selectivity and an update on subtype selective ligands.

(2014) Int J Environ Res Public Health 11

PubMed: 25162709 | PubMedCentral: PMC4198987 | DOI: 10.3390/ijerph110908709

(Å) Ref 1A52 Dimer Estradiol 2.8 [ 29 ] 1ERE Hexamer Estradiol 3.1 [ 30 ] 1ERR Dimer Raloxifene 2.6 [ 30 ] 3ERD Dimer Diethylstilbestrol 2.03 [ 31 ] 3ERT Monomer 4-Hydroxytamoxifen 1.9 [ 31 ] ... QKT Monomer Estradiol 2.2 [ 32 ] 1QKU Trimer Estradiol 3.2 [ 32 ] 1G50 Trimer Estradiol 2.9 [ 33 ] 1GWQ Dimer Raloxifene core 2.45 [ 34 ] 1GWR Dimer Estradiol 2.4 [ 34 ] 1L2I Dimer ( R,R )-5,11- cis -Diethyl-5,6,11,12-tetrahydrochrysene- 2,8-diol 1.95 [ 35 ] 1PCG Dimer Estradiol 2.7 [ 36 ] 1UOM Monomer 2-Phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3, 4-tetrahydroisoquinolin-6-ol 2.28 [ 37 ] 1R5K Trimer (2 E )-3-{4-[(1 E )-1,2-Diphenylbut-1-enyl]phenyl}acrylic acid 2.7 [ 38 ] 1SJ0 Monomer (2 S ,3 R )-2-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-3-(4-hydroxyphenyl)benzo[b][1,4]oxathiin-6-ol 1.9 [ 39 ] 1XP1 Monomer (2 S ,3 R )-2-(4-{2-[(3 R ,4 R )-3,4-Dimethylpyrrolidin-1-yl]ethoxy}phenyl)-3-(4-hydroxyphenyl)-2,3-dihydro-1,4-benzoxathiin-6-ol 1.8 [ 40 ] 1XP6 Monomer (2 S ,3 R )-2-(4-{2-[(3 S ,4 S )-3,4-Dimethylpyrrolidin-1-yl]ethoxy}phenyl)-3-(4-hydroxyphenyl)-2,3-dihydro-1,4-benzoxathiin-6-ol 1.7 [ 40 ] 1XP9 Monomer (2 S ,3 R )-3-(4-Hydroxyphenyl)-2-(4-{[(2 S )-2-pyrrolidin-1-ylpropyl]oxy}phenyl)-2,3-dihydro-1,4-benzoxathiin-6-ol 1.8 [ 40 ] 1XPC Monomer (2 S ,3 R )-3-(4-Hydroxyphenyl)-2-(4-{[(2 R )-2-pyrrolidin-1-ylpropyl]oxy}phenyl)-2,3-dihydro-1,4-benzoxathiin-6-ol 1.6 [ 40 ] 1X7E Dimer [5-Hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile 2.8 [ 41 ] 1X7R Monomer Genistein 2 [ 42 ] 1XQC Tetramer (1 S )-1-{4-[(9a R )-Octahydro-2 H -pyrido[1,2-a]pyrazin-2-yl]phenyl}-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol 2.05 [ 43 ] 1YIM Monomer (2 R ,3 R ,4 S )-3-(4-Hydroxyphenyl)-4-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]chroman-6-ol 1.9 [ 44 ] 1YIN Monomer (2 R ,3 R ,4 S )-5-Fluoro-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]chroman-6-ol 2.2 [ 44 ] 2AYR Monomer 6-(4-Methylsulfonyl-phenyl)-5-[4-(2-piperidin-1-ylethoxy)phenoxy]naphthalen-2-ol 1.9 [ 45 ] 2B23 Dimer 2.1 [ 46 ] 2BJ4 Dimer 4-Hydroxytamoxifen 2 [ 47 ] 1ZKY Dimer 4-[(1 S ,2 S ,5 S )-5-(Hydroxymethyl)-6,8,9-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol 2.25 [ 48 ] 2B1V Dimer 4-[(1 S ,2 S ,5 S )-5-(Hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol 1.8 [ 48 ] 2B1Z Dimer 17-Methyl-17-α-dihydroequilenin 1.78 [ 49 ] 2FAI Dimer 4-[(1 S ,2 S ,5 S ,9 R )-5-(Hydroxymethyl)-8,9-dimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol 2.1 [ 48 ] 2I0J Tetramer (3a S ,4 R ,9b R )-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 2.9 [ 50 ] 2G44 Dimer 4-[(1 S ,2 R ,5 S )-4,4,8-Trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol 2.65 - 2G5O Dimer (9α,13β,17β)-2-[(1 Z )-But-1-en-1-yl]estra-1,3,5(10)-triene-3,17-diol 2.3 - 2IOG Monomer N-[(1 R )-3-(4-Hydroxyphenyl)-1-methylpropyl]-2-[2-phenyl-6-(2-piperidin-1-ylethoxy)-1h-indol-3-yl]acetamide 1.6 [ 51 ] 2IOK Dimer N-[(1 R )-3-(4-Hydroxyphenyl)-1-methylpropyl]-2-(2-phenyl-1 H -indol-3-yl)acetamide 2.4 [ 51 ] 2JF9 Trimer 4-Hydroxytamoxifen 2.1 [ 52 ] 2JFA Dimer Raloxifene 2.55 [ 52 ] 2OCF Monomer Estradiol 2.95 [ 53 ] 2OUZ Monomer (5 R ,6 S )-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol 2 [ 54 ] 2P15 Dimer (17β)-17-{( E )-2-[2-(Trifluoromethyl)phenyl]vinyl}estra-1(10),2,4-triene-3,17-diol 1.94 [ 55 ] 2POG Dimer (3a S ,4 R ,9b R )-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-9-ol 1.84 [ 56 ] 2Q6J Dimer 4-[(Dimesitylboryl)(2,2,2-trifluoroethyl)amino]phenol 2.7 [ 57 ] 2Q70 Dimer (3a S ,4 R ,9b R )-2,2-Difluoro-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 1.95 [ 58 ] 2QE4 Dimer (3a S ,4 R ,9b R )-4-(4-Hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 2.4 [ 50 ] 2QA6 Dimer 4-(6-Hydroxy-1 H -indazol-3-yl)benzene-1,3-diol 2.6 [ 46 ] 2QA8 Dimer Genistein 1.85 [ 46 ] 2QAB Dimer 3-Ethyl-2-(4-hydroxyphenyl)-2 H -indazol-5- ol 1.89 [ 46 ] 2QGT Dimer (9β,11α,13α,14β,17α)-11-(methoxymethyl)estra-1(10),2,4-triene-3,17-diol 2.15 [ 46 ] 2QGW Dimer 3-Chloro-2-(4-hydroxyphenyl)-2 H -indazol-5-ol 2.39 [ 46 ] 2QH6 Dimer Diethyl (1 R ,2 S ,3 R ,4 S )-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate 2.7 [ 46 ] 2QR9 Dimer Dimethyl (1 R ,4 S )-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate 2 [ 46 ] 2QSE Dimer 4-(2-Amino-1-methyl-1 H -imidazo[4,5-b]pyridin-6-yl)phenol 1.85 [ 46 ] 2QXM Dimer 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyrid 2.3 [ 46 ] 2QXS Dimer Raloxifene 1.7 [ 59 ] 2QZO Dimer 4-[1-Allyl-7-(trifluoromethyl)-1h-indazol- 3-yl]bezene-1,3-diol 1.72 [ 59 ] 2R6W Dimer [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[2-(4-methylpiperidin-1-yl)ethoxy]phenyl}methanone 2 [ 60 ] 2R6Y Dimer [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone 2 [ 60 ] 3DT3 Dimer 5-(4-Hydroxyphenoxy)-6-(3-hydroxyphenyl)- 7-methylnapthalen-2-ol 2.4 [ 61 ] 3HLV Dimer (9β,13α,16β)-3,16-Dihydroxyestra- 1,3,5(10)-trien-17-one 3 - 3HM1 Dimer (9β,13α)-3-Hydroxyestra-1,3,5(10)-trien-17-one 2.33 - 3L03 Dimer (14β,15α,16α,17α)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol 1.9 - 3OS8 Tetramer 4-[1-Benzyl-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1, 3-diol 2.03 [ 59 ] 3OS9 Tetramer 4-[1-Allyl-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1,3-diol 2.3 [ 59 ] 3OSA Tetramer 4-[1-(3-Methylbut-2-en-1-yl)-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1,3-diol 2.3 [ 59 ] 2YAT Monomer Estradiol-pyridinium tetraacetic acid 2.6 [ 62 ] 2YJA Monomer Estradiol 1.82 [ 63 ] 3Q95 Dimer Estriol 2.05 - 3Q97 Dimer 4,4’-[(1 Z )-1-(4-Ethoxyphenyl)but-1-ene-1,2-diyl]diphenol; 4,4’-[2-(4-Ethoxyphenyl)but-1-ene-1,1-diyl]diphenol 2.1 - 3UU7 Dimer 4,4’-Propane-2,2-diyldiphenol 2.2 [ 64 ] 3UUA Dimer 4,4’-(1,1,1,3,3,3-Hexafluoropropane-2,2-diyl)diphenol 2.05 [ 64 ] 3UUC Tetramer 4,4’-(2,2-Dichloroethene-1,1-diyl)diphenol 2.1 [ 64 ] 3UUD Dimer Estradiol 1.6 [ 64 ] 4DMA Dimer 2’-Bromo-6’-(furan-3-yl)-4’-(hydroxymethyl)biphenyl-4-ol 2.3 [ 65 ] 4IU7 Dimer 4-[2-Ethyl-7-(trifluoromethyl)-2 H -indazol-3-yl]benzene-1, 3-diol 2.29 [ 66 ] 4IUI Dimer 4-[1-Butyl-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1, 3-diol 2.3 [ 66 ] 4IV2 Dimer 4-[1-(2-Methylpropyl)-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1,3-diol 2.14 [ 66 ] 4IV4 Dimer 4-[2-(2-Methylpropyl)-7-(trifluoromethyl)- 2h-indazol-3-yl]benzene-1,3-diol 2.3 [ 66 ] 4IVW Dimer 4-[2-Benzyl-7-(trifluoromethyl)-2 H -indazol-3-yl]benzene-1,3-diol 2.06 [ 66 ] 4IVY Dimer 4-[1-(But-3-en-1-yl)-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1,3-diol 1.95 [ 66 ] 4IW6 Dimer 4-[2-(But-3-en-1-yl)-7-(trifluoromethyl)-2 H -indazol-3-yl]benzene-1,3-diol 1.98 [ 66 ] 4IW8 Dimer 4-[1-(3-Methylbut-2-en-1-yl)-7-(trifluoromethyl)-1 H -indazol-3-yl]benzene-1,3-diol 2.04 [ 66 ] 4IWC Dimer 4,4’-Thiene-2,5-diylbis(3-methylphenol) 2.24 [ 66 ] 4IWF Dimer 2-Chloro-3’-fluoro-3-[( E )-(hydroxyimino)methyl]biphenyl- 4,4’-diol 1.93 [ 66 ] ijerph-11-08709-t002_Table 2 Table 2 Crystal structures of ERβ ligand binding domain bound with ligands in PDB.

Publication Year: 2014


PubMed ID is not available.

Published in 2014

PubMedCentral: PMC4207530

Crystal structure of the ER ligand binding domain (gray ribbon, PDB code 1ERE) is bound to native ligand (estradiol, red spheres).

Publication Year: 2014


Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer.

(2015) Oncol Lett 9

PubMed: 25435968 | PubMedCentral: PMC4246626 | DOI: 10.3892/ol.2014.2623

Hist_degree, degree of family history; non, no family history; 1ere degree, first degree family history; 2eme degree, second degree family history; inconnu, unknown.

Publication Year: 2015


The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor ? modulation, uncoupling nuclear and membrane activation.

(2014) EMBO Mol Med 6

PubMed: 25214462 | PubMedCentral: PMC4287935 | DOI: 10.15252/emmm.201404112

Results Comparison of the ERα LBD structure, of the coactivator interaction, and of the solubility/orientation in phospholipids bilayer model membranes after E 2 and E 4 binding In order to ga... n insight into the molecular mechanism of action of E 4, we first compared the crystal structures of ERα LBD complexed with E 3 (3Q95) or E 4 (3L03) to the published E 2 -ERα structure (1ERE) and we found all of them very similar in their overall conformation (Fig 1 A and B).

Publication Year: 2014